Overview

Dose-Escalation Study of SCD-101 in Sickle Cell Disease

Status:
Recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and clinical effects of SCD-101 when given to adults with sickle cell disease.
Phase:
Phase 1
Details
Lead Sponsor:
Invenux, LLC
Collaborator:
State University of New York - Downstate Medical Center